circCDK13-loaded small extracellular vesicles accelerate healing in preclinical diabetic wound models

Qilin Huang, Ziqiang Chu, Zihao Wang, Qiankun Li, Sheng Meng, Yao Lu, Kui Ma, Shengnan Cui, Wenzhi Hu, Wenhua Zhang, Qian Wei, Yanlin Qu, Haihong Li, Xiaobing Fu, Cuiping ZhangNature Communications 2024 · DOI

TL;DR

Diabetic wounds are a major challenge due to impaired healing. This study identifies a circular RNA, circCDK13, that promotes skin cell proliferation and migration. By packaging circCDK13 into engineered extracellular vesicles (sEVs), researchers successfully accelerated wound healing in preclinical diabetic models, offering a promising new therapeutic avenue.

What Problem Does This Paper Address?

Diabetes is a growing global health concern, and one of its most debilitating complications is the development of chronic, non-healing wounds. These wounds, often exacerbated by poor circulation and impaired immune function, significantly reduce patients' quality of life and impose a heavy economic burden. The underlying mechanisms for this delayed wound healing are complex, but it's understood that advanced glycation end products (AGEs) and hyperglycemia negatively impact the function of key skin repair cells like dermal fibroblasts and epidermal keratinocytes. While current treatments exist, their efficacy is often limited, highlighting the urgent need for novel therapeutic strategies. This paper addresses this gap by investigating the role of circular RNAs (circRNAs) in diabetic wound healing and developing a targeted delivery system for a promising therapeutic circRNA.

Methods

The researchers employed a multi-pronged approach:

  • circRNA Identification: They analyzed microarray data to identify circRNAs differentially expressed in diabetic wounds compared to normal wounds.
  • In Vitro Studies:
    • Cell Culture: Human dermal fibroblasts (HDFs) and human epidermal keratinocytes (HEKs) were used.
  • AGEs Simulation: AGE-BSA was used to mimic the diabetic wound microenvironment.
  • Gene Manipulation: siRNA was used to knock down circCDK13, and overexpression vectors were used to increase its levels.
  • Functional Assays: CCK-8 assays (proliferation), EdU incorporation (DNA synthesis), wound healing assays, and transwell migration assays were performed to assess cell behavior.
  • Molecular Mechanism: RNA pull-down assays, RIP-qPCR, FISH-IF, and western blots were used to investigate interactions between circCDK13, RNA-binding proteins (IGF2BP3), and downstream targets (CD44, c-MYC). m6A modification analysis was also conducted.
  • Extracellular Vesicle (sEV) Engineering:
    • sEV Production: Mesenchymal stem cells (MSCs) were engineered to overexpress circCDK13.
  • sEV Characterization: TEM, NTA, and western blot were used to confirm the identity, size, and protein markers of the sEVs.
  • sEV Uptake: CM-Dil labeled sEVs were used to track their internalization by HDFs and HEKs.
  • In Vivo Studies:
    • Animal Models: Preclinical models using male db/db diabetic mice and streptozotocin (STZ)-induced type I diabetic rats were established.
  • Treatment: Subcutaneous injection of engineered sEVs (circCDK13OE-SEVs) or control sEVs (N-sEVs) was administered.
  • Wound Assessment: Wound closure, re-epithelialization, granulation tissue formation, collagen deposition, and skin appendage regeneration were evaluated through gross observation, H&E staining, and Masson's trichrome staining. Protein expression of key markers was also assessed in wound tissues.

Datasets

  • Microarray Data: GSE114248 was used to identify differentially expressed circRNAs in diabetic foot ulcers (DFU) versus normal wounds (NWs).
  • Cell Lines: Human dermal fibroblasts (HDFs) and human epidermal keratinocytes (HEKs) were used.
  • Animal Models: Male db/db diabetic mice and STZ-induced type I diabetic rats were used.

Key Insights and Ideas

  • circCDK13 as a Therapeutic Target: The study identified circCDK13 as a circRNA that is downregulated in diabetic wounds. This is significant because it suggests that restoring its levels could be beneficial for healing, unlike some other circRNAs that are upregulated and detrimental.
  • Mechanism of Action: circCDK13 doesn't act alone. It interacts with IGF2BP3 in an m6A-dependent manner. This interaction is crucial for stabilizing CD44 and c-MYC mRNA, which are key players in cell proliferation and migration – processes vital for wound repair. This highlights a complex regulatory network involving circRNA, RNA-binding proteins, and mRNA stability.
  • sEVs as a Superior Delivery System: While MSC-derived sEVs (N-sEVs) showed some benefit, engineered sEVs overexpressing circCDK13 (circCDK13OE-SEVs) demonstrated significantly enhanced efficacy in promoting wound healing, both in vitro and in vivo. This underscores the potential of sEVs as a robust platform for delivering therapeutic RNA molecules.
  • Synergistic Effect: The research suggests a synergistic interaction between circCDK13 and IGF2BP3, where their combined action is more potent than either alone in promoting cell proliferation and migration.

Key Results

  • In Vitro:
    • circCDK13 knockdown inhibited HDF and HEK proliferation and migration.
  • circCDK13 overexpression promoted HDF and HEK proliferation and migration.
  • circCDK13OE-SEVs significantly rescued the inhibitory effects of AGE-BSA and high glucose on HDF and HEK proliferation and migration, outperforming N-sEVs.
  • circCDK13OE-SEVs increased the protein levels of IGF2BP3, c-MYC, CD44, and Cyclin D1 in HDFs and HEKs.
  • In Vivo:
    • Subcutaneous injection of circCDK13OE-SEVs significantly accelerated wound closure in db/db diabetic mice and STZ-induced type I diabetic rats compared to N-sEVs and control groups.
  • circCDK13OE-SEVs promoted re-epithelialization, granulation tissue formation, collagen deposition, and regeneration of skin appendages.
  • Wound tissues from circCDK13OE-SEV treated animals showed higher expression of IGF2BP3, c-MYC, and CD44.

Limitations and Future Work

  • sEV Loading Mechanism: The precise mechanisms by which circCDK13 is transferred into sEVs remain unknown. Elucidating this could lead to improved loading efficiency and therapeutic outcomes.
  • Clinical Translation: While promising, the study is preclinical. Further research is needed to assess the safety and efficacy in larger animal models and eventually in human clinical trials.
  • Specificity of circCDK13-IGF2BP3-mRNA Complex: While the study strongly suggests a ternary complex involving circCDK13, IGF2BP3, and CD44/c-MYC mRNA, further investigation is needed to confirm direct binding of circCDK13 or IGF2BP3 to these mRNAs and to identify any other involved mediators.
  • Long-term Effects: The study focused on wound healing over a specific period. Long-term effects and potential side effects of sEV treatment would need to be evaluated.

Summary updated

Abstract

Chronic wounds are a major complication in patients with diabetes. Here, we identify a therapeutic circRNA and load it into small extracellular vesicles (sEVs) to treat diabetic wounds in preclinical models. We show that circCDK13 can stimulate the proliferation and migration of human dermal fibroblasts and human epidermal keratinocytes by interacting with insulin-like growth factor 2 mRNA binding protein 3 in an N6-Methyladenosine-dependent manner to enhance CD44 and c-MYC expression. We engineered sEVs that overexpress circCDK13 and show that local subcutaneous injection into male db/db diabetic mouse wounds and wounds of streptozotocin-induced type I male diabetic rats could accelerate wound healing and skin appendage regeneration. Our study demonstrates that the delivery of circCDK13 in sEVs may present an option for diabetic wound treatment.
BibTeX
@inproceedings{huang2024circcdk,
  author = {Qilin Huang and Ziqiang Chu and Zihao Wang and Qiankun Li and Sheng Meng and Yao Lu and Kui Ma and Shengnan Cui and Wenzhi Hu and Wenhua Zhang and Qian Wei and Yanlin Qu and Haihong Li and Xiaobing Fu and Cuiping Zhang},
  title = {{circCDK13-loaded small extracellular vesicles accelerate healing in preclinical diabetic wound models}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-48284-3},
}
Figure